Yu KS - Search Results

1

Voriconazole-associated severe hyponatremia.

Kim KH, Lee S, Lee S, Yun NR, Kim NJ, Yu KS, Jang IJ, Park WB, Oh MD. Kim KH, et al. Among authors: yu ks. Med Mycol. 2012 Jan;50(1):103-5. doi: 10.3109/13693786.2011.587210. Epub 2011 Jun 15. Med Mycol. 2012. PMID: 21671829

2

Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP-450, in healthy volunteers.

Jang IJ, Yu KS, Shon JH, Bae KS, Cho JY, Yi SY, Shin SG, Ryu KH, Cho YB, Kim DK, Yoo SE. Jang IJ, et al. Among authors: yu ks. J Clin Pharmacol. 2000 Jul;40(7):752-61. doi: 10.1177/00912700022009512. J Clin Pharmacol. 2000. PMID: 10883417 Clinical Trial.

3

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.

Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, Shin SG. Yu KS, et al. Clin Pharmacol Ther. 2001 Apr;69(4):266-73. doi: 10.1067/mcp.2001.114231. Clin Pharmacol Ther. 2001. PMID: 11309556 Clinical Trial.

4

Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin.

Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, Jang IJ, Shin SG. Yu KS, et al. Clin Pharmacol Ther. 2001 Sep;70(3):228-36. doi: 10.1067/mcp.2001.117703. Clin Pharmacol Ther. 2001. PMID: 11557910 Clinical Trial.

5

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.

Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Cho JY, et al. Among authors: yu ks. Br J Clin Pharmacol. 2002 Apr;53(4):393-7. doi: 10.1046/j.1365-2125.2002.01366.x. Br J Clin Pharmacol. 2002. PMID: 11966672 Free PMC article. Clinical Trial.

6

Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.

Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS. Yu KS, et al. J Clin Pharmacol. 2004 Jan;44(1):73-82. doi: 10.1177/0091270003261321. J Clin Pharmacol. 2004. PMID: 14681344 Clinical Trial.

7

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Yu KS, et al. Clin Pharmacol Ther. 2004 Aug;76(2):104-12. doi: 10.1016/j.clpt.2004.03.009. Clin Pharmacol Ther. 2004. PMID: 15289787

8

Haplotype structure and allele frequencies of CYP2B6 in a Korean population.

Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, Jang IJ. Cho JY, et al. Among authors: yu ks. Drug Metab Dispos. 2004 Dec;32(12):1341-4. doi: 10.1124/dmd.104.001107. Epub 2004 Sep 21. Drug Metab Dispos. 2004. PMID: 15383491

9

A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.

Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG. Yi SY, et al. Among authors: yu ks. Clin Pharmacol Ther. 2004 Nov;76(5):418-27. doi: 10.1016/j.clpt.2004.08.002. Clin Pharmacol Ther. 2004. PMID: 15536457

10

Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.

Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG. Chung JY, et al. Among authors: yu ks. Clin Pharmacol Ther. 2005 Jun;77(6):486-94. doi: 10.1016/j.clpt.2005.02.006. Clin Pharmacol Ther. 2005. PMID: 15961980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

420 results

Search Page

Filters